Journal of ethnopharmacology · 2026
LingGui QiHua-3 decoction (LGQH-3) ameliorates cardiorenal dysfunction in HFpEF by restoring fluid homeostasis via the PCSK6/Corin/p38 MAPK/AQPs axis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liang Xiaoyu, Chen Ziyi, Liu Siyu, Wei Yue, Li Zhixuan, Mou Yunying, Liu Dongxin, Li Yao, Hao Xiaopeng, Huang Luqi, Dong Guoju
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: LingGui QiHua-3 decoction (LGQH-3) is a clinical formulation for heart failure with preserved ejection fraction (HFpEF) associated with fluid retention. As a derivative of Zhenwu Decoction, it embodies to the ethnopharmacological principles of warming "yang", promoting "qi" transformation, and draining water to manage cardiorenal fluid dysregulation. However, its pharmacological underlying mechanisms remain unclear.
AIM OF THE STUDY: This study aimed to determine whether LGQH-3 protects against HFpEF by restoring cardiorenal fluid metabolism, and to elucidate the underlying molecular mechanisms involved in coordinated cardiac and renal fluid regulation.
MATERIALS AND METHODS: HFpEF was induced in mice via high-fat diet and L-NAME administration. Mice model were evaluated by echocardiography, exercise tolerance, histopathology, and biochemical assays. Candidate pathways were identified through UHPLC-MS and network pharmacology, and subsequently validated by RT-qPCR, WB, ELISA, and immunohistochemistry. Mechanistic relevance was further examined in AC16 cardiomyocytes and HK-2 renal tubular epithelial cells using pharmacological inhibition.
RESULTS: LGQH-3 improved diastolic function and exercise tolerance, attenuated cardiac hypertrophy/fibrosis and renal injury, reduced pulmonary congestion, and increased urine output. Mechanistically, LGQH-3 inhibited pathological p38 MAPK activation and associated normalized the aberrent expression of cardiac AQP4 and renal AQP2. In parallel, it restored the PCSK6/Corin axis and reactivated natriuretic peptide signaling to re-establish fluid homeostasis. The in vitro findings were consist with the in vivo results, and pharmacological inhibition of p38 MAPK further supported the critical role of the PCSK6/Corin-p38 MAPK/AQPs cascade.
CONCLUSION: LGQH-3 alleviates cardiorenal dysfunction in HFpEF by restoring fluid homeostasis through regulation of the PCSK6/Corin-p38 MAPK/AQPs network, providing a pharmacological basis for its traditional application and clinical translational potential.
AIM OF THE STUDY: This study aimed to determine whether LGQH-3 protects against HFpEF by restoring cardiorenal fluid metabolism, and to elucidate the underlying molecular mechanisms involved in coordinated cardiac and renal fluid regulation.
MATERIALS AND METHODS: HFpEF was induced in mice via high-fat diet and L-NAME administration. Mice model were evaluated by echocardiography, exercise tolerance, histopathology, and biochemical assays. Candidate pathways were identified through UHPLC-MS and network pharmacology, and subsequently validated by RT-qPCR, WB, ELISA, and immunohistochemistry. Mechanistic relevance was further examined in AC16 cardiomyocytes and HK-2 renal tubular epithelial cells using pharmacological inhibition.
RESULTS: LGQH-3 improved diastolic function and exercise tolerance, attenuated cardiac hypertrophy/fibrosis and renal injury, reduced pulmonary congestion, and increased urine output. Mechanistically, LGQH-3 inhibited pathological p38 MAPK activation and associated normalized the aberrent expression of cardiac AQP4 and renal AQP2. In parallel, it restored the PCSK6/Corin axis and reactivated natriuretic peptide signaling to re-establish fluid homeostasis. The in vitro findings were consist with the in vivo results, and pharmacological inhibition of p38 MAPK further supported the critical role of the PCSK6/Corin-p38 MAPK/AQPs cascade.
CONCLUSION: LGQH-3 alleviates cardiorenal dysfunction in HFpEF by restoring fluid homeostasis through regulation of the PCSK6/Corin-p38 MAPK/AQPs network, providing a pharmacological basis for its traditional application and clinical translational potential.